Voytek Faber – Trademark Portfolio

Entity Type: 01

Voytek Faber holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 5 Nice Classification classes. The owner is based in Davie, FL.

11860 W. State Road 84, Suite B15

Davie, FL 33325

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

X XERA
X XERA
Abandoned 2021

Trademark Classifications

Voytek Faber's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Voytek Faber have?

Voytek Faber has 1 U.S. trademark filed with the USPTO.

What trademark classes does Voytek Faber file in?

Voytek Faber files trademarks across 5 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What is Voytek Faber's trademark registration success rate?

Voytek Faber has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.